Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for ScPharmaceuticals Inc. (SCPH:NASDAQ), powered by AI.
ScPharmaceuticals Inc. is currently trading at $5.67. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for ScPharmaceuticals Inc. on Alpha Lenz.
ScPharmaceuticals Inc.'s P/E ratio is -3.0.
“ScPharmaceuticals Inc. trades at a P/E of -3.0 (undervalued) with modest ROE of -337.0%.”
Ask for details →ScPharmaceuticals Inc. is a cutting-edge pharmaceutical company specializing in the development and commercialization of innovative products for the treatment of heart failure and other critical disorders. The primary objective of the company is to simplify the drug delivery process, particularly for chronic conditions that typically require hospitalization. By focusing on user-friendly therapies designed for home use, ScPharmaceuticals aims to reduce the need for costly hospital visits, thereby transforming patient care and efficiency within the healthcare sector. Noteworthy features of ScPharmaceuticals include its development of advanced subcutaneous formulations that enable self-administration by patients. These innovations are particularly significant for the healthcare industry, as they not only improve patient comfort and adherence to treatment plans but also offer potential cost savings to healthcare systems globally. The company's impact is pronounced in sectors addressing acute heart conditions, where the demand for convenient, at-home treatment solutions is climbing. Since its founding, ScPharmaceuticals Inc. has been a pivotal player in the biotechnology and pharmaceuticals market, leveraging cutting-edge research to meet pressing medical needs and redefine boundaries in drug delivery methods.
“ScPharmaceuticals Inc. trades at a P/E of -3.0 (undervalued) with modest ROE of -337.0%.”
Ask for details →ScPharmaceuticals Inc. (ticker: SCPH) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 162 employees. Market cap is $252M.
The current price is $5.67 with a P/E ratio of -2.96x and P/B of 18.95x.
ROE is -336.97% and operating margin is -178.29%. Annual revenue is $36M.